ABSTRACT
Abstract Background: Therapeutic hypothermia is used in adults and neonates after cardiac arrest, but its efficiency in children under 18 years old is still uncertain. Objective: To evaluate the effectiveness and risks of therapeutic hypothermia after cardiac arrest in children under 18 years of age through a systematic review. Methods: A systematic review was performed in January 2022 in the MEDLINE, SciELO, Cochrane, and LILACS databases. Inclusion criteria: randomized controlled trials (RCTs) performed in humans. Articles from other typologies, published more than 10 years ago, or with volunteers over 18 years old were excluded. Results: Four studies were identified, of which 3 were analyzed; all of them were of moderate quality according to the Jadad Scale and the Cochrane Collaboration tool. The studies indicated that lowering the temperature did not improve data on mortality and adverse events. Two studies did not identify statistically significant differences (p > 0.05) considering hypothermia in relation to normothermia in terms of survival, safety, and global neurobehavioral and cognitive function. The other study did not show improved serum biomarker concentrations. Conclusion: The results found in this review do not support the use of therapeutic hypothermia after pediatric cardiac arrest, as this intervention did not provide any apparent benefits in terms of safety, adverse events, survival, and neurological impact. We recommend the conduction of new RCTs using the measurement of serum biomarkers to better evaluate the effectiveness of the intervention.
ABSTRACT
Introdução: Displasia broncopulmonar (DBP) é uma grave complicação entre pré-termos, com incidência inversamente proporcional à idade gestacional. Resulta de processo inflamatório com desenvolvimento pulmonar anormal, gerando graves consequências. Apesar de serem limitadas e não afetarem substancialmente a evolução da doença, as opções terapêuticas para prevenção e tratamento da DBP são importantes, porém carecem de melhor elucidação. Objetivos: Abordar aspectos recentes da literatura quanto à prevenção e tratamento da DBP. Métodos: Revisão de literatura na base de dados MEDLINE, em 2021, incluindo ensaios clínicos controlados e randomizados, realizados em humanos e nos últimos 5 anos, excluindo estudos não diretamente relacionados ao tema. Resultados: A incidência de DBP foi menor naqueles casos leves expostos à budesonida inalatória, óleo de peixe intravenoso contendo emulsão lipídica (OP) e ácido docosahexaenoico (DHA). Houve aumento da sobrevida com uso de hidrocortisona em baixas doses, dexametasona com redução gradual da dose, por 42 dias, e dexametasona associada a corticosteroides pós-natais (este ainda com redução dos prejuízos no neurodesenvolvimento). Hidrocortisona, dexametasona, dipropianato de hidrofluoalcano-beclometasona inalado e OP reduziram o tempo ou a necessidade de ventilação e oxigenoterapia. A mortalidade foi menor nos estudos envolvendo hidrocortisona e elevada no que avaliou budesonida. As principais complicações foram sepse, retinopatia, hemorragia intraventricular e enterocolite necrosante, nos estudos abordando DHA, hidrocortisona, dexametasona e óxido nítrico inalado. Conclusão: Abordagens terapêuticas satisfatórias foram os glicocorticoides associado à terapia ventilatória e à abordagem precoce. Não houve benefícios com uso de ventilação com insuflações sustentadas, administração de dipropionato de hidrofluoralcano-beclometasona inalada e DHA.
Introduction: Bronchopulmonary dysplasia (BPD) is a complication among preterms, with an incidence inversely proportional to gestational age. It results from an inflammatory process that causes abnormal lung development, with severe consequences. Although therapeutic options are limited and do not substantially strike the course of the disease, they are important tools and need further elucidation. Purpose: Address the most recent aspects of the literature regarding the prevention and treatment of BPD. Methods: A literature review was carried out in the MEDLINE database, in 2021, in which only controlled and randomized clinical studies performed in humans in the last 5 years were included. Studies that were not directly related to the theme were excluded. Results: The incidence of BPD was lower in those cases exposed to inhaled budesonide, intravenous fish oil containing lipid emulsion (FO) and docosahexaenoic acid (DHA). There was improvement in survival with a lowdose use of hydrocortisone, dexamethasone with gradual dose reduction, and dexamethasone associated with postnatal corticosteroids (which generated reduction in neurodevelopmental impairments as well). Hydrocortisone, dexamethasone, inhaled hydrofluoalkane-beclomethasone dipropynate and FO reduced the time or need for ventilation and oxygen therapy. The main complications were sepsis, retinopathy, intraventricular hemorrhage and necrotizing enterocolitis in studies that addressed DHA, hydrocortisone, dexamethasone and inhaled nitric oxide. Conclusion: The therapeutic approaches that proved to be conclusive were the use of glucocorticoids associated with ventilatory therapy and an early approach. No benefits were found with the use of ventilation with sustained inflation, administration of inhaled hydrofluoralkane-beclomethasone dipropionate and DHA.
Subject(s)
Humans , Infant, Newborn , Bronchopulmonary Dysplasia/therapy , Pneumonia , Infant, Premature , Beclomethasone , GlucocorticoidsABSTRACT
SUMMARY Vertebral Artery Dissection (VAD) is a rare condition that can be caused by a wide amplitude of neck movement, which injures the vessel wall and can cause ischemia in the cerebellum. We present a 37-year-old man with herniated lumbar disc and allergic rhinosinusitis, which caused sneezing spells. After one of these bouts with a ricochet of the head, he presented C3 misalignment with local pain. Twenty-one days later, affected by a new crisis, he presented left temporal headache, nystagmus, and vertigo. After 3 days, Magnetic Resonance Imaging (MRI) identified 2 regions of cerebellar ischemia and filling failure of the right vertebral artery. After 2 days, Computed Angiotomography (CT Angiography) was performed and showed right VAD with a local thrombus, without aneurysmal signs. Transcranial Doppler did not indicate an increase in blood flow from this artery. The suggested treatment involved administration of anticoagulant Apixabana 5mg, 12/12h, for 3 months, until the condition was reevaluated with new Angio CT and MRI. It was recommended that the patient was released from work for 1 month and forbidden from doing intense physical exercises for 3 months; however, due to setbacks, these deadlines were extended until a new appointment, 4 months after the first visit. The new tests showed no changes, indicating that the condition was stable. This case aims to indicate the possible investigations of the diagnosis and therapeutic options of the rare association between VAD with cerebellar infarction in a well-documented case.
RESUMO A Dissecção da Artéria Vertebral (DAV) é quadro raro que pode ser causado por movimentação de grande amplitude do pescoço, que lesiona a parede desse vaso, podendo provocar isquemia no cerebelo. Apresentamos um homem de 37 anos, com hérnia de disco e rinossinusite alérgica que lhe causava crises de espirros em salva (CE). Após uma dessas crises com ricocheteamento da cabeça, apresentou desalinhamento de C3 com dor local. Vinte e um dias depois, acometido por nova crise, apresentou cefaleia temporal esquerda, nistagmo e vertigem. Decorridos 3 dias, o paciente foi submetido a Ressoânncia Magnética (RM), que identificou 2 regiões de isquemia cerebelar e enchimento comprometido da artéria vertebral direita. Após 2 dias, foram feitos Angiotomografia Computadorizada (Angio TC), que constatou DAV direita com trombo local, sem sinais aneurismáticos, e Doppler Transcraniano, que não indicou aumento do fluxo sanguíneo dessa artéria. O tratamento sugerido envolvia administração de anticoagulante Apixabana 5mg, 12/12h, por 3 meses, até que o quadro fosse reavaliado com novas Angio TC e RM. Foi recomendado que o paciente ficasse afastado do trabalho por 1 mês e de exercícios físicos intensos por 3 meses, porém devido a contratempos, esses prazos foram prorrogados até nova consulta, 4 meses após a primeira. Os novos exames não apresentaram alterações, indicando que o quadro estava estável. Esse caso tem como objetivo indicar as possíveis investigações do diagnóstico e opções terapêuticas da rara associação entre DAV com infarto cerebelar em caso bem documentado.